Breakthrough - T1DM and Chronic Kidney Disease

Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA). Participation in this research will last about 5 years. Assess safety, tolerability, and efficacy of transplanted islet cells and immunomodulation with Tegoprubart in combination with anti-thymocyte globulin (ATG), etanercept and with everolimus in adults with brittle T1D and chronic kidney disease (stage 2-3a).

NCT Number	NCT07592000
Lead Sponsor	University of Chicago Collaborators: Breakthrough T1D
Conditions	Diabete Type 1, Chronic Kidney Disease
Enrollment	10 participants
Start Date	2027-04-29
Primary Completion	2030-01-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-08